ClinicalTrials.gg
Sign In
CompletedNCT07600645Updated Oct 23, 2026

Contact Lens Trial Fitting Experience

An interventional study of Lens A ( stenfilcon A ) in Presbyopia, sponsored by CooperVision International Limited (CVIL). Completed at 2 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment

Updated Oct 23, 2026Now CompletedStart date moved+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Study summary

This study will assess a trial fitting experience with contact lenses.

Read the detailed description

This study is designed to evaluate a contact lens fitting experience utilizing an at home trial kit.

02

Conditions studied

  • Presbyopia

Browse trials for

03

In context

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

This study's enrollment of 25 is below the median of 61 across 276 interventional studies indexed under Presbyopia.

Browse Presbyopia studies →

Lead sponsor

CooperVision International Limited (CVIL) is the lead sponsor of 138 studies on the registry; 6 are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 66 (89%) have results posted.

Browse CooperVision International Limited (CVIL) studies →All CooperCompanies studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. They are at least 40 years of age.
  2. They understand their rights as a research participant and are willing and able to sign a Statement of .
  3. They habitually wear MyDay sphere or MyDay Energys contact lenses (including sphere lenses for monovision, or sphere lenses for distance vision correction and spectacles for near vision correction).
  4. They have a minimum reading add of +0.75DS (based on their manifest refraction) and no more than +2.50DS.
  5. They have spherical equivalent refractive error between +4.50 to -11.00DS (some restrictions apply based on near add availability)
  6. They have refractive astigmatism of no greater than 0.75DC in each eye.
  7. They are able to achieve distance HCHL visual acuity of +0.10 logMAR or better in each eye with manifest refraction.
  8. They report at least one near-vision difficult symptom consistent with presbyopia as evidenced by a response of 'slight difficult' or worse on ³ 1 item of the Near Activity Visual Questionnaire (NAVQ-P) at screening.

Exclusion criteria

Exclusion Criteria:

  1. Is participating in any concurrent clinical or research trial.
  2. They have an ocular disorder which would normally contraindicate contact lens wear.
  3. They have a systemic disorder which would normally contraindicate contact lens wear.
  4. They are pseudophakic or aphakic.
  5. They have had corneal refractive surgery.
  6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
  7. Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable.
  8. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrollment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Lens A ( stenfilcon A)

    All participants will wear lens A

    Device: Lens A ( stenfilcon A )

Interventions

  • DeviceLens A ( stenfilcon A )

    15 minutes of daily wear

06

What researchers measure

Primary outcomes

  1. Participant Lens Fitting Experience

    Participant's readiness to finalize a multifocal contact lens prescription after using an at home trial kit based on a scale of 1- 5 (1 - Good and 5 - Bad).

    Time frame: At the End of 15 minutes of daily wear

07

Study locations

2 sites
  • Bellaire Family Eye Care
    Bellaire, Texas 77401, United States
  • Drs. Mcintyre Garza Avila & Jurica
    Corpus Christi, Texas 78411, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Jul 2026, 1 month.

Of 87 industry-sponsored interventional studies with no phase under Presbyopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's 1 month is below that.

Counting every sponsor, half of 129 studies reached it within 10 months; a quarter within 3 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Sep 2026 → Jul 2026 and completion Sep 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 22, 2026
StartActual
May 15, 2026
Primary completionActual
Jul 7, 2026was Sep 2026
CompletionActual
Jul 7, 2026was Sep 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 23, 2026
Start date
May 31, 2026→May 15, 2026 (actual)
Oct 23, 2026
Primary completion
Sep 1, 2026→Jul 7, 2026 (actual)
Oct 23, 2026
Study completion
Sep 1, 2026→Jul 7, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Completed
    Start date May 31, 2026→May 15, 2026 (now actual)
    Primary completion Sep 1, 2026→Jul 7, 2026 (now actual)
    Study completion Sep 1, 2026→Jul 7, 2026 (now actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07600645
Lead sponsor
CooperVision International Limited (CVIL)
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 15, 2026
Primary completion
Jul 7, 2026
Completion
Jul 7, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Presbyopia →

Other studies from this sponsor

CooperVision International Limited (CVIL) →

Start the discussion